AGI 134

Drug Profile

AGI 134

Alternative Names: AGI-134; Alpha-gal glycosphingolipid - BioLineRx; Beta-galactosidase glycosphingolipid - BioLineRx; Glycosphingolipid beta-galactosidase immunotherapy

Latest Information Update: 03 Apr 2017

Price : $50

At a glance

  • Originator Agalimmune
  • Developer BioLineRx
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 23 Mar 2017 Agalimmune has been acquired by BioLineRx
  • 23 Mar 2017 Agalimmue plans a first-in-human phase I/II trial in Solid tumours in the first half of 2018
  • 16 Apr 2016 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top